当前位置: X-MOL 学术Ann. Hematol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma.
Annals of Hematology ( IF 3.5 ) Pub Date : 2020-02-05 , DOI: 10.1007/s00277-020-03942-6
Do Young Kim 1 , Joo-Seop Chung 1 , Jae-Cheol Jo 2 , Su-Hee Cho 3 , Ho-Jin Shin 1
Affiliation  

Autologous stem cell transplant (ASCT) is an effective treatment for non-Hodgkin lymphoma (NHL). However, recent supply issues and toxicity of carmustine have necessitated a new conditioning regimen. We conducted a multicenter, phase II study of BEB (busulfan, etoposide, and bendamustine) conditioning regimen for ASCT in patients with NHL. Thirty-one patients were enrolled and underwent ASCT with the BEB conditioning regimen. The most common subtype was diffuse large B-cell lymphoma (n = 23, 74.2%). Nine patients (29.0%) had a history of relapse, and 18 patients (58.1%) received more than 2 lines of chemotherapy before ASCT. A median number of 6.05 × 106/kg CD34 cells were infused, and all patients engrafted after a median period of 11 days. Thirteen patients (41.9%) experienced neutropenic fever, and 16 patients (51.6%) had grade 3 or 4 toxicities during ASCT. No one had a documented infection, veno-occlusive disease, or treatment-related death. Three-month complete remission rate was 81.8%. Median follow-up period of 15 months showed 6 patients (19.4%) relapsed or progressed and 3 patients died. The estimated 2-year progression-free survival and overall survival rate were 73.0% and 89.8%, respectively. Our results show that BEB conditioning regimens for ASCT are feasible with tolerable toxicity in patients with NHL.

中文翻译:

II期BEB(苯达莫司汀,依托泊苷和环丁砜)调理方案在非霍奇金淋巴瘤中自体干细胞移植的安全性和有效性的II期研究。

自体干细胞移植(ASCT)是非霍奇金淋巴瘤(NHL)的有效治疗方法。但是,最近的供应问题和卡莫司汀的毒性已经需要一种新的调理方案。我们对NHL患者进行ASCT的BEB(白消安,依托泊苷和苯达莫司汀)调理方案进行了多中心,II期研究。纳入了31例患者,并使用BEB调理方案进行了ASCT。最常见的亚型是弥漫性大B细胞淋巴瘤(n = 23,74.2%)。9名患者(29.0%)有复发史,18名患者(58.1%)在ASCT之前接受了超过2线的化疗。中位数为6.05×106 / kg的CD34细胞被注入,中位时间为11天后所有患者均被植入。13名患者(41.9%)发生了中性粒细胞减少症,16名患者(51。6%)在ASCT期间具有3或4级毒性。没有人有感染,静脉阻塞性疾病或与治疗有关的死亡的记录。三个月的完全缓解率为81.8%。15个月的中位随访期显示6例(19.4%)复发或进展,3例死亡。估计的2年无进展生存期和总生存率分别为73.0%和89.8%。我们的结果表明,对于NHL患者,ASB的BEB调理方案可行且毒性耐受。分别。我们的结果表明,对于NHL患者,ASB的BEB调理方案可行且毒性耐受。分别。我们的结果表明,对于NHL患者,ASB的BEB调理方案可行且毒性耐受。
更新日期:2020-02-06
down
wechat
bug